Summary & Overview
HCPCS G9927: Documentation of Trial-Related Anticoagulation Exclusion
HCPCS Level II code G9927 is used to document the clinician’s reason(s) for not prescribing an FDA-approved anticoagulant when a patient is enrolled in a clinical trial for atrial fibrillation or atrial flutter. The code standardizes capture of trial-related treatment decisions and supports administrative clarity when usual anticoagulation is intentionally withheld because of protocol restrictions or investigational therapy use. Nationally, consistent use of this code helps payers and providers track instances where enrollment in research alters standard care pathways and assists in claims adjudication and quality reporting where trial participation is relevant.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for G9927, the expected service setting, and how this documentation code fits into ambulatory cardiology workflows. The publication outlines typical use cases, common modifiers and administrative considerations (Data not available in the input for payor-specific rules), and links the code to clinical scenarios involving atrial fibrillation/atrial flutter management. This summary is intended to inform coding staff, clinicians, and revenue-cycle teams about the purpose and operational role of HCPCS Level II code G9927 in national practice.
Billing Code Overview
HCPCS Level II code G9927 documents the clinician’s recorded reason(s) for not prescribing an FDA-approved anticoagulation because the patient is currently enrolled in a clinical trial related to atrial fibrillation or atrial flutter treatment. This code captures the clinical rationale when trial participation precludes the use of standard, approved anticoagulant therapy.
-
Service type: Clinical documentation of treatment decision-making related to anticoagulation in the context of clinical trial enrollment
-
Typical site of service: Outpatient cardiology clinic or other ambulatory care setting where atrial fibrillation/atrial flutter is managed and clinical trial enrollment is confirmed
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with persistent atrial fibrillation presents to a cardiology clinic participating in an institutional clinical trial of a novel antiarrhythmic device-based therapy. The patient has a CHA2DS2-VASc score indicating anticoagulation would ordinarily be recommended, but enrollment in the randomized trial requires withholding FDA‑approved oral anticoagulants while investigational therapy and standardized trial protocols are followed. The treating cardiologist documents discussion of thromboembolic risk, informed consent for trial participation, and the specific system reason(s) for not prescribing an FDA‑approved anticoagulant, including trial protocol requirements, monitoring plans (frequent INR or safety assessments if applicable), and alternative risk‑mitigation strategies (e.g., trial-specific antiplatelet regimen, close surveillance, eligibility criteria that exclude concurrent anticoagulation).
Workflow steps:
-
Patient referred to electrophysiology clinic for atrial fibrillation management and potential trial enrollment.
-
Informed consent obtained by authorized research personnel; treating clinician reviews anticoagulation implications.
-
Clinician documents the explicit system reason(s) for not prescribing an FDA‑approved anticoagulant using billing code
G9927in the medical record and communicates plan to research team and primary care provider. -
Ongoing follow-up visits include documentation of trial status, reassessment of stroke risk, and notation of any changes requiring initiation of FDA‑approved anticoagulation.